

Prof.Dr.Tayfun EYİLETEN

Özgeçmiş

Adı : Tayfun
Soyadı : Eyiletten
Ünvan : Profesör Doktor
Doğum Tarihi : 28 Kasım 1965
Uyruk : T.C.
Medeni Durum : Evli

EĞİTİM

Doçent Doktor : Nefroloji Bilim Dalı, Gülhane Tıp Fakültesi,
Tarih : Aralık 2010 – Temmuz 2017

Staj Tahsili : Transplantation Unit of Hospital of University of Pennsylvania
(UPENN), Philadelphia USA.
Tarih : Aralık 2010- Aralık 2011

Yardımcı Doçent : Nefroloji Bilim Dalı, Gülhane Tıp Fakültesi,
Tarih : Eylül 2006 – Aralık 2010.

Yan Dal : Nefroloji Bilim Dalı, Gülhane Tıp Fakültesi,
Tarih : Temmuz 2003- Ağustos 2006.

İç Hastalıları Uzmanı : İç Hastalıkları Bölümü, Ankara Mevki Hastane,
Tarih : Kasım 1999 – Temmuz 2003

Uzmanlık Eğitimi : İç Hastalıkları Ana Bilim Dalı, Gülhane Tıp Fakültesi
Tarih : Eylül 1995– Kasım 1999.

Pratisyen Doktor : TSK
Tarih : Mayıs 1991 - Eylül 1995

Tıp Fakültesi : Gülhane Tıp Fakültesi
Tarih : 1983 - 1990.

KURSLAR

Kurs : 14 th Budapest Nephrology School
Süre : 6 gün.
Tarih : 25/08/2007 – 30/08/2007
Adres : Semmervils University, Budapest, Hungary

Kurs : Board Review Course in Nephrology
Süre : 5 gün
Tarih : Mayıs 2008
Adres : Harvard Medical School, Boston, USA

Kurs : Board Review Course in Nephrology
Süre : 5 gün
Tarih : Mayıs 2010
Adres : Harvard Medical School, Boston, USA

Kurs : Transplantation Course
Süre : 5 gün
Tarih : Ağustos 2010
Adres : Barcelona Clinic SPAIN.

Kurs : Transplantation Course
Süre : 2 gün
Tarih : Ekim 2011
Adres : 2011 ATC Congress in Philadelphia, USA

Kurs : Transplantation Course
Süre : 1 gün.
Tarih : Mart 2015
Adres : 2015 ASN Congress in Atlanta, USA

ARAŐTIRMA KONULARI : Hipertansiyon, Bbrek Transplantasyonu, Yoęun
Bakım.

H(Hirsch) İndeks : 28.

SCI-Expanded yer alan yayın sayısı : 69

Glhane Tıp Fakltesinde Öğretim Üyelięi 2006-2017. (Sınıf II, III ve IV)

Yakın Doęu Üniversitesi Tıp Fakltesinde (Sınıf III) ve Saęlık Bilimleri Enstitsnde 2014-
2018.

A. SCI kapsamındaki ORJİNAL MAKALELER

- 1) Mas MR, Saglamkaya U, Kubar A, Colakoglu M, Ateskan U, Erdem H, Nalbant S, **Eyiletten T**, Comert B, Unal T, Kocabalkan F.: Hepatitis G virus infection among patients undergoing hemodialysis. *Nephron*. 1998 Oct;80(2):247-8.
- 2) Uçkaya G, Ozata M, Sonmez A, Kinalp C, **Eyiletten T**, Bingol N, Koc B, Kocabalkan F, Ozdemir IC.: Plasma leptin levels strongly correlate with plasma renin activity in patients with essential hypertension. *Hormon Metab Resc*. 1999 Jul;31(7):435-8.
- 3) Uckaya G, Ozata M, Sonmez A, Kinalp C, **Eyiletten T**, Bingol N, Koc B, Kocabalkan F, Ozdemir IC.: Is leptin associated with hypertensive retinopathy? *J Clin Endocrinol Metab*. 2000 Feb;85(2):683-7.
- 4) Sonmez A, Kisa U, Uckaya G, **Eyiletten T**, Comert B, Koc B, Kocabalkan F, Ozata M.: Effects of losartan treatment on T-cell activities and plasma leptin concentrations in primary hypertension. *J Renin Angiotensin Aldosteron Syst*;2(2):112-6.
- 5) Yenicesu M, Yilmaz MI, Caglar K, Sonmez A, **Eyiletten T**, Acikel C, Kilic S, Bingol N, Bingol S, Vural A.: Blockade of the renin-angiotensin system increases plasma adiponectin levels in type-2 diabetic patients with proteinuria. *Nephron Clin Pract*. 2005;99(4):c115-21
- 6) Yilmaz MI, Sonmez A, Caglar K, Gok DE, **Eyiletten T**, Yenicesu M, Acikel C, Bingol N, Kilic S, Oguz Y, Vural A.: Peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist increases plasma adiponectin levels in type 2 diabetic patients with proteinuria. *Endocrine*. 2004 Dec;25(3):207-14
- 7) Vural A, Yilmaz MI, Caglar K, Aydin A, Sonmez A, **Eyiletten T**, Acikel C, Gulec B, Kozak O, Oner K.: Assessment of oxidative stress in the early posttransplant period: comparison of cyclosporine A and tacrolimus-based regimens. *Am J Nephrol*. 2005 May-Jun;25(3):250-5.
- 8) Sonmez A, Dogru T, Yilmaz MI, Ocal R, Ozgurtas T, Kilic S, **Eyiletten T**, Tasci I, Erbil K, Kocar IH.: Soluble CD40 ligand levels in patients with hypertension. *Clin Exp Hypertens*. 2005 Nov;27(8):629-34
- 9) Yenicesu M, Yilmaz MI, Caglar K, Sonmez A, **Eyiletten T**, Kir T, Acikel C, Bingol N, Oguz Y, Ikizler TA, Vural A.: Adiponectin level is reduced and inversely correlated with the degree of proteinuria in type 2 diabetic patients. *Clin Nephrol*. 2005 Jul;64(1):12-9.
- 10) Yilmaz MI, Saglam M, Caglar K, Cakir E, Sonmez A, Ozgurtas T, Aydin A, **Eyiletten T**, Ozcan O, Acikel C, Tasar M, Genctoy G, Erbil K, Vural A, Zoccali C.: The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. *Am J Kidney Dis*. 2006 Jan;47(1):42-50.
- 11) Yilmaz MI, Saglam M, Caglar K, Cakir E, Ozgurtas T, Sonmez A, **Eyiletten T**, Yenicesu M, Acikel C, Oguz Y, Ozcan O, Bozlar U, Erbil K, Aslan I, Vural A.: Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation. *Transplantation*. 2005 Dec 27;80(12):1660-6

- 12) Yilmaz MI, Korkmaz A, Kaya A, Sonmez A, Caglar K, Topal T, **Eyileten T**, Yenicesu M, Acikel C, Oter S, Yaman H, Aktug H, Oguz Y, Vural A, Ikizler TA.: Hyperbaric oxygen treatment augments the efficacy of a losartan regime in an experimental nephrotic syndrome model. *Nephron Exp Nephrol*. 2006;104(1):e15-22.
- 13) Dogru T, Sonmez A, Tasci I, Yilmaz MI, Kilic S, Ozgurtas T, **Eyileten T**, Erbil MK, Kocar IH.: Plasma adiponectin and insulin resistance in new onset hypertension. *Endocrine* 2006 Jun;29(3):405-8.
- 14) Sonmez A, Kisa U, Uckaya G, **Eyileten T**, Kinalp C, Yilmaz MI, Dogru T, Turan M, Kocar IH.: Asymptomatic kindred of patients with coronary events have increased peripheral T-cell activities. *Heart Vessels* 2006 Jul;21(4):242-6.
- 15) Caglar K, Yilmaz MI, Sonmez A, Cakir E, Kaya A, Acikel C, **Eyileten T**, Yenicesu M, Oguz Y, Bilgi C, Oktenli C, Vural A, Zoccali C.: ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. *Kidney Int*. 2006 Aug;70(4):781-7.
- 16) Caglar K, Yilmaz MI, Saglam M, Cakir E, Kilic S, **Eyileten T**, Sonmez A, Oguz Y, Oner K, Ors F, Vural A, Yenicesu M.: Endothelial dysfunction and fetuin A levels before and after kidney transplantation. *Transplantation*. 2007 Feb 27;83(4):392-7.
- 17) Yilmaz MI, Sonmez A, Caglar K, Celik T, Yenicesu M, **Eyileten T**, Acikel C, Oguz Y, Yavuz I, Vural A.: Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. *Nephrology (Carlton)*. 2007 Apr;12(2):147-53.
- 18) Yilmaz MI, Saglam M, Sonmez A, Caglar K, Cakir E, Kurt Y, **Eyileten T**, Tasar M, Acikel C, Oguz Y, Vural A, Yenicesu M.: Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan. *Blood Purif*. 2007;25(4):327-35
- 19) Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, Caglar K, **EyiletenT**, SonmezA, Cakir E, YenicesuM, Lindholm B, Stenvinkel P and Axelsson J. Serum Visfatin Concentration And Endothelial Dysfunction in Chronic Kidney Disease. *Nephrol Dial Transplant*. 2007 23(3):959-65
- 20) Caglar K, Yilmaz MI, SaglamM, CakirE, AcikelC, **Eyileten T**, Yenicesu M, Oguz Y, Vural A, Carrero JJ, Axelsson J, Lindholm B, Stenvinkel P.: Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. *Clin J Am Soc Nephrol*. 2008 Jan;3(1):61-8.
- 21) Sonmez A, Yilmaz MI, Korkmaz A, Topal T, Caglar K, Kaya A, **Eyileten T**, Yenicesu M, Oguz Y, Basal S, Ipcioglu OM, Vural A.: Hyperbaric oxygen treatment augments the efficacy of cilazapril and simvastatin regimens in an experimental nephrotic syndrome model. *Clin Exp Nephrol*. 2008, 12(2):110-8
- 22) Yilmaz MI, Saglam M, Qureshi AR, Carrero JJ, Caglar K, **Eyileten T**, Sonmez A, Cakir E, Oguz Y, Vural A, Yenicesu M, Stenvinkel P, Lindholm B Axelsson J.: Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. *Nephrol Dial Transplant*. 2008 (23)1621-1627

- 23) Yilmaz MI, Sonmez A, Saglam M, Qureshi AR, Carrero JJ, Caglar K, **Eyileten T**, Cakir E, Oguz Y, Vural A, Yenicesu M, Lindholm B, Stenvinkel P, Axelsson J.: ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. *J Am Soc Nephrol*, 2008(19): 388-395
- 24) Caglar K, Yilmaz MI, Saglam M, Cakir E, Kilic S, Sonmez A, **Eyileten T**, Yenicesu M, Oguz, Tasar M, Vural A, Ikizler TA, Stenvinkel P, Lindholm B.: Serum Fetuin-A Concentration and Endothelial Dysfunction in Chronic Kidney Disease. *Nephron Clin Pract* 2008;108:c233-c240
- 25) Oguz Y, Yilmaz MI, Acikel C, **Eyileten T**, Caglar K, Oktenli C, Yenicesu M, Vural A.: The relationship between adiponectin levels and degree of proteinuria in patients with nephrotic and non-nephrotic proteinuria. *Ren fail*. 2009, 31(1):29-35
- 26) Yilmaz MI, Axelsson J, Sonmez A, Carrero JJ, Saglam M, **Eyileten T**, Caglar K, Kirkpantur A, Celik T, Oguz Y, Vural A, Yenicesu M, Lindholm B, Stenvinkel P. : Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria. *Clin J Am Soc Nephrol* 2009 Mar;4(3):535-541
- 27) Yilmaz MI, Sonmez A, Saglam M, Gulec M, Kilic S, **Eyileten T**, Caglar K, Oguz Y, Vural A, Yenicesu M, Zoccali C.: Hemoglobin is inversely related to flow-mediated dilatation in chronic kidney disease. *Kidney Int*. 2009 Jun;75(12):1316-21.
- 28) Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, Caglar K, **Eyileten T**, Sonmez A, Oguz Y, Aslan I, Vural A, Yenicesu M, Stenvinkel P, Lindholm B, Axelsson J. : Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/NAMPT. A novel marker of endothelial damage? *Clin Transplant*. 2009 Mar-Apr;23(2):241-8
- 29) Afsar B, Elsurer R, **Eyileten T**, Yilmaz MI, Yenicesu M. Antibody response following hepatitis B vaccination in dialysis patients: Does depression and life quality matter? *Vaccine* 2009 Sep 25;27(42):5865-9
- 30) Sonmez A, Yilmaz MI, Saglam M, Kilic S, **Eyileten T**, Uckaya G, Caglar K, Oguz Y, Vural A, Yenicesu M, Kutlu M, Kinalp C, Zoccali C.: The relationship between hemoglobin levels and endothelial functions in diabetes mellitus. *Clin J Am Soc Nephrol*. 2010 Jan;5(1):45-50
- 31) Yilmaz MI, Qureshi AR, Carrero JJ, Saglam M, Suliman ME, Caglar K, **Eyileten T**, Sonmez A, Oguz Y, Vural A, Yenicesu M, Axelsson J.: Predictors of carotid artery intima-media thickness in chronic kidney disease and kidney transplant patients without overt cardiovascular disease. *Am J Nephrol*. 2010;31(3):214-21
- 32) Yilmaz MI, Sonmez A, Saglam M, Yaman H, Cayci T, Kilic S, **Eyileten T**, Caglar K, Oguz Y, Vural A, Yenicesu M, Axelsson J.: Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway? *Nephrol Dial Transplant*. 2010(10):3250-6
- 33) Afsar B, Afsar RE, Sen ST, Kirkpantur A, **Eyileten T**, Yilmaz MI, Caglar K.: Simple renal cysts and circadian blood pressure: Are they related to each other in patients with hypertension? *Int Urol Nephrol*. 2010 Apr. 13

- 34) Yilmaz MI, Carrero JJ, Martin-Ventura JL, Sonmez A, Saglam M, Celik T, Yaman H, Yenicesu M, **Eyileten T**, Moreno JA, Egido J, Bianco-Colio LM.: Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: Effects on soluble TWEAK, PTX3 and flow-mediated dilation. *Clin J Am Soc Nephrol* 2010 Jul;5(7):1174-81
- 35) Afsar B, Elsurer R, Yilmaz MI, **Eyileten T**, Yenicesu M.: Irritable bowel syndrome in haemodialysis: Prevalence, link with quality of life and depression. *Nephrology(Carlton)*.2010 Mar;15(2):197-202
- 36) **Eyileten T**, Sonmez A, Saglam M, Cakir E, Caglar K, Oguz Y, Vural A, Yenicesu M, Yilmaz MI Effect of renin-angiotensin-aldosterone system(RAAS) blockade on visfatin levels in diabetic nephropathy. *Nephrology(Carlton)*.2010 Mar;15(2):225—9
- 37) Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Demirkaya E, **Eyileten T**, Caglar K, Oguz Y, Vural A, Yenicesu M, Zoccali C.: FGF-23 and vascular dysfunction in patients with stage3 and 4 chronic kidney disease. *Kidney int*.2010 Oct;78(7):679-85
- 38) Yilmaz MI, Sonmez A, Karaman M, Ay SA, Saglam M, Yaman H, Kilic S, **Eyileten T**, Caglar K, Oguz Y, Vural A, Yenicesu M, Zoccali C.: Low triiodothyronine alters flow-mediated vasodilatation in advanced nondiabetic kidney disease. *Am J Nephrol*.2011;33(1):25-32
- 39) Yilmaz MI, Sonmez A, Ortiz A, Saglam M, Kilic S, **Eyileten T**, Caglar K, Oguz Y, Vural A, Cakar M, Egido J, Altun B, Yenicesu M, Blanco-Colio LM, Carrero JJ. Soluble TWEAK and PTX3 in Nondialysis CKD Patients: Impact on Endothelial Dysfunction and Cardiovascular Outcomes. *Clin J Am Soc Nephrol*. 6(4):785-792, (2011).
- 40) Yilmaz MI, Stenvinkel P, Sonmez A, Saglam M, Yaman H, Kilic S, **Eyileten T**, Caglar K, Oguz Y, Vural A, Cakar M, Altun B, Yenicesu M, Carrero JJ. Vascular health, systemic inflammation and progressive reduction in kidney function; clinical determinants and impact on cardiovascular outcomes. *Nephrol Dial Transplant*. 2011 Nov 26(11):3537-43.
- 41) Yilmaz MI, Sonmez A, Qureshi AR, Saglam M, Steininkel P, Yaman H, **Eyileten T**, Caglar K, Oguz Y, Taslipinar A, Vural A, Gok M, Unal HU; Yenicesu M, Carrero JJ. Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease. *Clin J Am Soc Nephrol*. 2011 Jul 6(7):1617-25. Epub 2011 Jun 23
- 42) Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, **Eyileten T**, Caglar K, Oguz Y, Vural A, Yenicesu M, Mallamaci F, Zoccali C. Comparison of Calcium Acetate and Sevelamer on Vascular Function and Fibroblast Growth Factor 23 in CKD patients A Randomized Clinical Trial. *Am J Kidney Dis*. 2012;59(2):177-185
- 43) Kanbay M, Yilmaz MI, Apetrii M, Saglam M, Yaman H, Unal HU, Gok M, Caglar K, Oguz Y, Yenicesu M, Cetinkaya H, **Eyileten T**, Acikel C, Vural A, Covic A.: Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients. *Am J Nephrol*. 2012;36(3):228-37.

- 44) Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Turker T, Unal HU, Gok M, Cetinkaya H, **Eyileten T**, Oguz Y, Caglar K, Vural A, Mallamaci F, Zoccali C.: Longitudinal analysis of vascular function and biomarkers of metabolic bone disorders before and after transplantation. *Am J Nephrol*. 2013;37(2):126-34.
- 45) Solak Y, Yilmaz MI, Saglam M, Caglar K, Verim S, Unal HU, Gok M, Demirkaya E, Gaipov A, Kayrak M, Cetinkaya H, **Eyileten T**, Turk S, Vural A.: Red cell distribution width is independently related to endothelial dysfunction in patients with chronic kidney disease. *Am J Med Sci*. 2013 Aug 7.(Epub)
- 46) Yilmaz MI¹, Sonmez A, Saglam M, Yaman H, Unal HU, Gok M, Cetinkaya H, **Eyileten T**, Oguz Y, Sari S, Yildirim AO, Vural A, Carrero JJ, Blanco-Colio LM. Soluble TWEAK plasma levels increase after renal transplantation and associate with the improvement of endothelial function. *Eur J Clin Invest*. 2013 Dec;43(12):1250-7. doi: 10.1111/eci.12166. Epub 2013 Sep 20.
- 47) Yilmaz MI, Solak Y, Saglam M, Cayci T, Acikel C, Unal HU, **Eyileten T**, Oguz Y, Sari S, Carrero JJ, Stenvinkel P, Covic A, Kanbay M.: The relationship between IL-10 levels and cardiovascular events in patients with CKD. *Clin J Am Soc Nephrol*. 2014 Jul;9(7):1207-16. doi: 10.2215/CJN.08660813. Epub 2014 May 1.
- 48) Kanbay M, Solak Y, Unal HU, Kurt YG, Gok M, Cetinkaya H, Karaman M, Oguz Y, **Eyileten T**, Vural A, Covic A, Goldsmith D, Turak O, Yilmaz MI. Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. *Int Urol Nephrol*. 2014 Aug;46(8):1619-25. doi: 10.1007/s11255-014-0730-1. Epub 2014 May 23.
- 49) Yilmaz MI, Demirkaya E, Acikel C, Saldir M, Akar S, Cayci T, Saglam M, Unal HU, Gok M, Polat A, Cetinkaya H, **Eyileten T**, Sari S, Yildirim AO, Sonmez A, Oguz Y, Vural A, Ozen S, Carrero JJ.: Endothelial function in patients with familial Mediterranean fever-related amyloidosis and association with cardiovascular events. *Rheumatology (Oxford)*. 2014 Nov;53(11):2002-8. doi: 10.1093/rheumatology/keu231. Epub 2014 Jun 6.
- 50) Yilmaz MI, Siriopol D, Saglam M, Kurt YG, Unal HU, **Eyileten T**, Gok M, Cetinkaya H, Oguz Y, Sari S, Vural A, Mititiuc I, Covic A, Kanbay M.: Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. *Kidney Int*. 2014 Dec;86(6):1213-20. doi: 10.1038/ki.2014.227. Epub 2014 Jul 2.
- 51) Kanbay M, Siriopol D, Saglam M, Kurt YG, Gok M, Cetinkaya H, Karaman M, Unal HU, Oguz Y, Sari S, **Eyileten T**, Goldsmith D, Vural A, Veisa G, Covic A, Yilmaz MI.: Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients.
- 52) Unal HU, Çelik M, Gökoğlan Y, Çetinkaya H, Gök M, Karaman M, Yilmaz Mİ, **Eyileten T**, Oğuz Y. Mitral annular calcification and the serum osteocalcin level in patients with chronic kidney disease. *Ren Fail*. 2014 Nov;36(10):1481-5. doi: 10.3109/0886022X.2014.962421. Epub 2014 Sep 16.

53) Yilmaz MI, Sonmez A, Saglam M, Kurt YG, Unal HU, Karaman M, Gok M, Cetinkaya H, **Eyileten T**, Oguz Y, Vural A, Mallamaci F, Zoccali C. Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy. *Am J Nephrol*. 2014;40(3):208-14. doi: 10.1159/000366169. Epub 2014 Oct 10.

54) Yilmaz MI, Sonmez A, Saglam M, Cayci T, Kilic S, Unal HU, Karaman M, Cetinkaya H, **Eyileten T**, Gok M, Oguz Y, Vural A, Mallamaci F, Zoccali C. A longitudinal study of inflammation, CKD-mineral bone disorder, and carotid atherosclerosis after renal transplantation. *Clin J Am Soc Nephrol*. 2015 Mar 6;10(3):471-9. doi: 10.2215/CJN.07860814. Epub 2014 Dec 26.

55) Sonmez A, Yilmaz MI, Saglam M, Unal HU, Gok M, Cetinkaya H, Karaman M, Haymana C, **Eyileten T**, Oguz Y, Vural A, Rizzo M, Toth PP. The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease. *Lipids Health Dis*. 2015 Apr 16;14:29. doi: 10.1186/s12944-015-0031-4.

56) Solak Y, Yilmaz MI, Siritopol D, Saglam M, Unal HU, Yaman H, Gok M, Cetinkaya H, Gaipov A, **Eyileten T**, Sari S, Yildirim AO, Tonbul HZ, Turk S, Covic A, Kanbay M. Serum neutrophil gelatinase-associated lipocalin is associated with cardiovascular events in patients with chronic kidney disease. *Int Urol Nephrol*. 2015 Dec;47(12):1993-2001. doi: 10.1007/s11255-015-1136-4. Epub 2015 Oct 26.

57) Celik T, Yilmaz MI, Balta S, Ozturk C, Unal HU, Aparci M, Karaman M, Demir M, Yildirim AO, Saglam M, Kilic S, **Eyileten T**, Aydin İ, Iyisoy A. The Relationship Between Plasma Whole Blood Viscosity and Cardiovascular Events in Patients With Chronic Kidney Disease. *Clin Appl Thromb Hemost*. 2016 Jan 1:1076029616634888. doi: 10.1177/1076029616634888. [Epub ahead of print]

58) Kanbay M, Afsar B, Siritopol D, Unal HU, Karaman M, Saglam M, **Eyileten T**, Gezer M, Verim S, Oguz Y, Vural A, Ortiz A, Johnson RJ, Covic A, Yilmaz MI. Relevance of uric acid and asymmetric dimethylarginine for modeling cardiovascular risk prediction in chronic kidney disease patients. *Int Urol Nephrol*. 2016 Jul;48(7):1129-36. doi: 10.1007/s11255-016-1271-6. Epub 2016 Mar 23.

59) Yilmaz MI, Siritopol D, Saglam M, Unal HU, Karaman M, Gezer M, Kilinc A, **Eyileten T**, Guler AK, Aydin İ, Vural A, Oguz Y, Covic A, Ortiz A, Kanbay M. Osteoprotegerin in Chronic Kidney Disease: Associations with Vascular Damage and Cardiovascular Events. *Calcif Tissue Int*. 2016 Aug;99(2):121-30. doi: 10.1007/s00223-016-0136-4. Epub 2016 Mar 26.

60) Afsar B, Yilmaz MI, Siritopol D, Unal HU, Saglam M, Karaman M, Gezer M, Sonmez A, **Eyileten T**, Aydin I, Hamcan S, Oguz Y, Covic A, Kanbay M. Thyroid function and cardiovascular events in chronic kidney disease patients. *J Nephrol*. 2017 Apr;30(2):235-242. doi: 10.1007/s40620-016-0300-y. Epub 2016 Apr 2.

61) Kanbay M, Afsar B, Siritopol D, Unal HU, Karaman M, Saglam M, Gezer M, Taş A, **Eyileten T**, Guler AK, Aydin İ, Oguz Y, Tarim K, Covic A, Yilmaz MI. Endostatin in chronic kidney disease: Associations with inflammation, vascular abnormalities, cardiovascular events and survival. *Eur J Intern Med*. 2016 Sep;33:81-7. doi: 10.1016/j.ejim.2016.06.033. Epub 2016 Jul 7.

62) Haciosmanoglu T, Karacalioglu AO, **Eyileten T**, Ince S, Arslan N.: A different scintigraphic approach to evaluate the glomerular filtration rate. *Rev Esp Med Nucl Imagen Mol*. 2017 Mar 28. pii: S2253-654X(16)30215-3. doi: 10.1016/j.remn.2017.01.015. [Epub ahead of print]

63) Gungor O, Unal HU, Guclu A, Gezer M, **Eyileten T**, Guzel FB, Altunoren O, Erken E, Oguz Y, Kocyigit I, Yilmaz MI.: IL-33 and ST2 levels in chronic kidney disease: Associations with inflammation, vascular abnormalities, cardiovascular events, and survival. *PLoS One*. 2017 Jun 14;12(6):e0178939. doi: 10.1371/journal.pone.0178939. eCollection 2017

64) Eroglu E, Unal HU, Guclu A, Kocyigit I, Karaman M, Saglam M, Gezer M, Tas A, Zararsiz G, **Eyileten T**, Aydin İ, Oguz Y, Gungor O, Yilmaz MI.: The association of profilin-1 levels with survival in chronic kidney disease. *Eur J Clin Invest*. 2017 Dec;47(12). doi: 10.1111/eci.12839. Epub 2017 Oct 27.

B. VAKA TAKDİMLERİ ve EDİTÖRE MEKTUPLAR

1) Y. Oguz, M. Yilmaz, **T. Eyileten**, K. Caglar, M. Yenicesu, A. Kaya, M. Tasar, M. Saglam, L. Doganci, B. Gulec.: Persistent mediastinal and axillary lymph node tuberculosis in a renal transplant patient with successful outcome. *Transplant Proc*. 2006 Jun;38(5):1336-40.

2) **T.Eyileten**, F.Dede, M.Yenicesu, G. Celebi, A.Vural.:Idiopathic tubulointerstitial nephritis and uveitis—'TINU syndrome'. *Nephrol Dial Transplant*. 2008 Feb 23(2)

3) Afsar B, Yilmaz MI,**Eyileten T**.:Do patients with uric acid stones exhibit abnormal circadian blood pressure--a hypothesis. *Nephrol Dial Transplant.*, 24(6):2004, (2009).

4) Sengul E, **Eyileten T**, Ozcan A, Yilmaz MI, Yenicesu M.:Anti-glomerular basement membrane disease with nephrotic proteinuria. *Clin Nephrol.*, 72(2):157-9, (2009).

5) Sengul E, **Eyileten T**, Ozcan A, Yilmaz MI, Yenicesu M.:Diffuse alveolar hemorrhage as an unusual presentation of systemic lupus erythematosus. *Rheumatol Int.*, (2009)